Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trump Administration's Rx Drug Price Disclosure Reg Seen As Unworkable

Executive Summary

Lawyers say CMS proposed rule requiring TV ads to disclose drug's list price wouldn't survive First Amendment suit and competitors have no reason to try to enforce it.

You may also be interested in...



After DTC Rule Tossed Out In Court, Attention Turns (Again) To Congress

HHS lacks authority to require drug price disclosures in TV ads, judge rules. Even if legislation were to explicitly give the Trump Administration such authority, First Amendment issues would still linger.

DTC Ad Final Rule Means Reliance On PhRMA Program Risks Enforcement Action – Azar

Nevertheless, the Pharmaceutical Research and Manufacturers of America announces enhancement of its voluntary drug pricing disclosures program, a Medicines Assistance Tool website that links to individual company sites, in response to the US rule.

DTC Ad Final Rule Means Reliance On PhRMA Program Risks Enforcement Action – Azar

Nevertheless, the Pharmaceutical Research and Manufacturers of America announces enhancement of its drug pricing disclosures voluntary program, a Medicines Assistance Tool website that links to individual company sites, in response to the US rule.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS124106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel